RELATED STUDY
Modulation of l-α-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids
Key Findings: This study aimed to evaluate the pharmacology of GPR55 and the pharmacologic effects of various cannabinoids in search of novel targets of GPR55.
Results found:
- CB1 receptor antagonists are both agonists and inhibitors of l-α-lysophosphatidylinositol (LPI) signaling
- GW405833, a CB2 ligand, acts as a partial agonist of GPR55, while enhancing LPI signaling
- Δ9-tetrahydrocannabivarin (THC), cannabidivarin (CBDV), and cannabigerovarin (CBG) are also inhibitors of LPI.
Type of Study: Laboratory Study
Study Result: Inconclusive
Study Location(s): Israel, United Kingdom
Year of Pub: 2012
Cannabinoids Studied: Cannabidiol (CBD), Cannabigerol (CBG), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Cannabigerolic Acid (CBG-a), CP-x Synthetic Cannabinoids, AM-x Synthetic Cannabinoids, JWH-x Synthetic Cannabinoids, HU-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, AB-x Synthetic Cannabinoids, Tetrahydrocannabivarin (THCV), Lysophosphatidylinositol (LPI), Cannabidivarin (CBDV)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB2, GPCR 55, TRPA1, TRPV1, TRPM8
